Imfinzi savings card: as little as $0 an infusion with commercial insurance

Imfinzi is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Imfinzi is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameImfinzi

Authorized genericdurvalumab

Regular genericdurvalumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Imfinzi?

The original

–

Brand nameThe maker’s card

IMFINZI Co-pay Savings Program (AstraZeneca Access 360)

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

Or call 1-844-275-2360.

In the maker’s words

“Eligible patients may pay as little as $0 per infusion for IMFINZI and/or IMJUDO.”

From the maker’s offer on myaccess360.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Imfinzi itself, from the same company, sold without the brand name, and usually for less. For now Imfinzi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Imfinzi is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Non-small cell lung cancer (NSCLC)
Small cell lung cancer
Bladder cancer
Liver cancer (hepatocellular carcinoma)
Stomach cancer (gastric or gastroesophageal junction)
Endometrial (uterine) cancer that is dMMR
Biliary tract cancer (bile ducts and gallbladder)

What the FDA label says

IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:
in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-authorized test.
in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC).
in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Source: the FDA label for Imfinzi (AstraZeneca Pharmaceuticals LP), August 31, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked October 27, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/imfinzi/